The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response (CCyR). An increasing number of patients also achieve deep molecular responses (MR). We determined the frequency and significance of deep MR after TKI therapy for CML in CP. MR included: major molecular response (MMR), MR4, MR4.5, and undetectable...
BACKGROUND:The impact of FMS‐like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear.
METHODS:Patients with newly diagnosed AML were divided among 3 cytogenetic subgroups: core binding factor (CBF) AML, NK‐AML, and poor‐risk AML.
RESULTS:In total, 481 patients were included:...
BACKGROUND:Anemia is a frequent side effect of imatinib in patients with chronic myeloid leukemia (CML). Erythropoietic‐stimulating agents have been used for treatment of imatinib‐induced anemia. There are no data on long‐term safety of erythropoietic‐stimulating agents in CML patients.
METHODS:The records of chronic phase CML patients who received treatment with imatinib were reviewed for use of...
BACKGROUND:Clonal evolution is frequently detected in patients developing resistance to imatinib. The outcome of patients with clonal evolution treated with second generation tyrosine kinase inhibitors is not known.
METHODS:The authors analyzed the outcome of 177 CML patients after second tyrosine kinase inhibitor therapy.
RESULTS:Ninety‐five patients were in chronic phase, 30 had clonal evolution,...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.